Literature DB >> 22763660

Is extracapsular tumour spread a prognostic factor in patients with early breast cancer?

Erion Dobi1, Fernando Bazan, Armelle Dufresne, Martin Demarchi, Cristian Villanueva, Loic Chaigneau, Philipe Montcuquet, Arben Ivanaj, Jean Loup Sautière, Yolande Maisonnette-Escot, Laurent Cals, Marie Paule Algros, Anne-Sophie Woronoff, Xavier Pivot.   

Abstract

BACKGROUND: This study searched for extra capsular tumour spread (ECS) as a prognostic factor for recurrence in terms of Disease Free Survival (DFS) and Overall Survival (OS). PATIENTS AND METHODS: For this study, from a retrospective database of the Doubs cancer registry, 823 eligible women with node positive breast cancer treated from February 1984 to November 2000 were identified. The following factors were evaluated: ECS, numbers of involved nodes, histological tumour grade, tumour size, status of estrogen and progesterone receptors, and age of patient. A Cox proportional hazards method was used to search for significant factors related to OS and DFS length.
RESULTS: In the multivariate analysis, factors related to DFS length were found to be: tumour grade (aHR 0.76, 95 % CI 0.61-0.96, p = 0.02), ECS status (aHR 0.7, 95 % CI 0.49-0.96, p = 0.03), progesterone (PgR) status (aHR 0.63, 95 % CI 0.44-0.85 p = 0.008), number of nodes involved (aHR 0.75, 95 % CI 0.56-1, p = 0.05). The multivariate analysis for OS found as significant factors: tumour grade (aHR 0.76, 95 % CI 0.61-0.95; p = 0.02) and PgR status (aHR 0.8, 95 % CI 0.56-0.99, p = 0.02).
CONCLUSIONS: This study might suggest taking into account ECS status in the adjuvant decision-making process.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22763660     DOI: 10.1007/s10147-012-0439-z

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  27 in total

1.  Factors influencing short and long term survival of breast cancer patients.

Authors:  J W Berg; G F Robbins
Journal:  Surg Gynecol Obstet       Date:  1966-06

2.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.

Authors:  M Overgaard; M B Jensen; J Overgaard; P S Hansen; C Rose; M Andersson; C Kamby; M Kjaer; C C Gadeberg; B B Rasmussen; M Blichert-Toft; H T Mouridsen
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

3.  Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.

Authors:  Günther Gruber; Marco Bonetti; M Laura Nasi; Karen N Price; Monica Castiglione-Gertsch; Carl-Magnus Rudenstam; Stig B Holmberg; Jurij Lindtner; Rastko Golouh; John Collins; Diana Crivellari; Antonino Carbone; Beat Thürlimann; Edda Simoncini; Martin F Fey; Richard D Gelber; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

4.  Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

Authors:  M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler
Journal:  N Engl J Med       Date:  1997-10-02       Impact factor: 91.245

5.  The role of regional nodal irradiation in the management of patients with early-stage breast cancer treated with breast-conserving therapy.

Authors:  F A Vicini; E M Horwitz; M D Lacerna; D M Brown; J White; C F Dmuchowski; V R Kini; A Martinez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-12-01       Impact factor: 7.038

6.  Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node.

Authors:  Gert G Van den Eynden; Melanie K Vandenberghe; Pieter-Jan H van Dam; Cecile G Colpaert; Peter van Dam; Luc Y Dirix; Peter B Vermeulen; Eric A Van Marck
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

Review 7.  Impact of gene expression profiling tests on breast cancer outcomes.

Authors:  Luigi Marchionni; Renee F Wilson; Spyridon S Marinopoulos; Antonio C Wolff; Giovanni Parmigiani; Eric B Bass; Steven N Goodman
Journal:  Evid Rep Technol Assess (Full Rep)       Date:  2007-12

Review 8.  Young age and outcome for women with early-stage invasive breast carcinoma.

Authors:  Ping Zhou; Abram Recht
Journal:  Cancer       Date:  2004-09-15       Impact factor: 6.860

9.  Implications of extranodal spread in node positive breast cancer: a review of survival and local recurrence.

Authors:  J A Bucci; C W Kennedy; J Burn; D J Gillett; H L Carmalt; M J Donnellan; M G Joseph; S C Pendlebury
Journal:  Breast       Date:  2001-06       Impact factor: 4.380

10.  Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy.

Authors:  C Leonard; M Corkill; J Tompkin; B Zhen; D Waitz; L Norton; J Kinzie
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

View more
  4 in total

1.  Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer.

Authors:  Sura Aziz; Elisabeth Wik; Gøril Knutsvik; Tor Audun Klingen; Ying Chen; Benedicte Davidsen; Hans Aas; Turid Aas; Lars A Akslen
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

2.  Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up.

Authors:  Marco Invernizzi; Chiara Corti; Gianluca Lopez; Anna Michelotti; Luca Despini; Donatella Gambini; Daniele Lorenzini; Elena Guerini-Rocco; Stefania Maggi; Marianna Noale; Nicola Fusco
Journal:  BMC Cancer       Date:  2018-09-29       Impact factor: 4.430

3.  Prognostic value of extranodal extension in axillary lymph node-positive breast cancer.

Authors:  XiaoXi Ma; Xia Yang; Wentao Yang; Ruohong Shui
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

4.  Breast Cancer Systemic Treatments and Upper Limb Lymphedema: A Risk-Assessment Platform Encompassing Tumor-Specific Pathological Features Reveals the Potential Role of Trastuzumab.

Authors:  Marco Invernizzi; Anna Michelotti; Marianna Noale; Gianluca Lopez; Letterio Runza; Massimo Giroda; Luca Despini; Concetta Blundo; Stefania Maggi; Donatella Gambini; Nicola Fusco
Journal:  J Clin Med       Date:  2019-01-24       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.